Kappa Sante
- Company typePrivate
- Founded2003
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Kappa Sante does
Kappa Santé is a France-based clinical research organization (CRO) founded in 2003, specializing in epidemiology, pharmaco-epidemiology, real-world evidence (RWE), and health economics and outcomes research (HEOR). The company serves pharmaceutical, biotechnology, and medical device companies requiring European clinical development support, with primary customers being pharma and biotech sponsors and a secondary focus on medical device manufacturers needing European regulatory and market access evidence. Core service offerings are organized around four pillars: Early Clinical Development (clinical strategy, study design, regulatory and ethics submissions, project management, clinical monitoring, data management and biostatistics, medical writing, clinical safety), Late Clinical Development (scaled trial execution with delivery discipline), RWE & HEOR (observational study design, real-world data sourcing and governance, analytics, regulatory and access alignment), and Medical Devices (clinical evidence development for European regulatory needs). The business operates on a project-based professional services revenue model, engaging sponsors directly through enterprise sales and RFP/RFI processes. Go-to-market is direct enterprise field sales targeting pharma and biotech buyers across Europe, with no disclosed pricing tiers or productized offerings.
Since its acquisition and full integration into APICES CRO, a Madrid-headquartered European CRO, Kappa Santé has operated as an integrated unit within a larger pan-European structure. The combined entity maintains offices in Madrid (HQ) and Paris, with co-founders Stéphane Schück (MD, MSc) and Nathalie Texier (MPharm, MSc) continuing in leadership roles. The integration expanded service breadth and geographic reach while preserving the operational discipline and senior oversight model that defined the standalone firm. No proprietary technology platforms, AI/ML capabilities, or patented assets are disclosed; the competitive positioning rests on domain expertise, regulatory knowledge across European jurisdictions, and specialized methodological strength in epidemiology and RWE.
Kappa Sante firmographics
Firmographics- Name
- Kappa Sante
- Legal name
- Kappa Santé
- Website
- https://kappasante.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Kappa Sante industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
- akta.pro primary industry
- Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL)
- akta.pro secondary industry
- Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)
Keywords
Where Kappa Sante is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Kappa Sante business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- CRO Professional Services: Kappa Santé generates revenue through professional services fees for clinical development, RWE, HEOR, and medical device clinical evidence services. Revenue is earned through project-based engagements with pharmaceutical and biotech sponsors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Kappa Sante product offering
Product offeringCore offering
Kappa Santé is a European contract research organization delivering clinical development, real-world evidence (RWE), health economics and outcomes research (HEOR), and clinical evidence services for medical devices. Offerings are organized around four core solutions — Early Clinical Development, Late Clinical Development, RWE & HEOR, and Medical Devices — delivered through sub-services spanning clinical strategy, study design, country and site feasibility, regulatory and ethics submissions, project management, clinical monitoring, data management and biostatistics, medical writing, and clinical safety. The portfolio supports sponsors from first European execution through late-phase delivery and post-marketing evidence generation.
Product overview
Kappa Sante, now part of APICES CRO, is a European contract research organization (CRO) offering integrated clinical development and real-world evidence services. The company operates as a unified service portfolio organized around four core solutions: Early Clinical Development, Late Clinical Development, RWE & HEOR (Real-World Evidence and Health Economics Outcomes Research), and Medical Devices. These solutions are delivered through specialized sub-services including clinical strategy and study design, regulatory submissions, project management, clinical monitoring, data management and biostatistics, medical writing, and safety monitoring for clinical development; and observational study design, data sourcing and governance, data analytics, and regulatory access alignment for RWE and HEOR. The portfolio functions as a modular service offering where clients can engage individual services or comprehensive end-to-end support across the drug and medical device development lifecycle.
Differentiator
Problem solved
Functional benefit
Products and services
- Early Clinical Development Clinical development services for sponsors moving from protocol to first European execution, covering clinical strategy, study design, regulatory submissions, and early-phase operations; for pharmaceutical and biotech sponsors.
- Late Clinical Development Clinical development services emphasizing scale, consistency, and delivery discipline for larger-scale trial execution across Europe; for pharmaceutical and biotech sponsors running late-phase programs.
- RWE & HEOR Real-World Evidence and Health Economics Outcomes Research services providing observational study design, real-world data sourcing, governance, advanced analytics, and regulatory and access alignment when outcomes data is required beyond controlled trials; for pharmaceutical, biotech, and medical device sponsors.
- Medical Devices Clinical evidence development services supporting European regulatory and market needs for medical devices; for medical device manufacturers needing compliant clinical evidence for EU submissions and market access.
Companies that use Kappa Sante
Customer profileSegments2 records
Ideal customer profiles2 records
Kappa Sante technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kappa Sante partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- APICEScoreKappa Santé has been fully integrated into APICES CRO, a European clinical research organization. This integration combines Kappa Santé's expertise in RWE, HEOR, and clinical development with APICES' broader European clinical trial capabilities. The integration strengthens execution capabilities while maintaining the operational discipline and senior oversight that defined Kappa Santé. This is a strategic acquisition that expands service offerings and geographic reach within the European CRO market.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
Kappa Sante competitors and assessment
Company assessmentBroad incumbents
- Medpace: Mid-to-large global CRO offering full-service clinical development across all phases; comparable to Kappa in core clinical operations but with far greater scale, geographic reach, and therapeutic breadth.
- Eurofins Scientific: Global testing and CRO services group with European footprint providing central labs, clinical trial support, and pharma services; broader portfolio but overlapping with Kappa's trial support capabilities.
- ICON plc: Top-5 global CRO with extensive European operations covering clinical development, RWE, and biostatistics; competes for the same European sponsors but at much larger scale.
Direct peers
- NAMSA: World's largest medical device-focused CRO; directly comparable to Kappa's Medical Devices clinical evidence service line and competes for European medtech sponsors.
- Worldwide Clinical Trials: Mid-size global CRO focused on complex clinical trials across multiple therapeutic areas, with comparable mid-market positioning and full-service clinical development offerings.
- Cytel: Specialist biostatistics, data management, and RWE/HEOR services provider; directly comparable to Kappa's data management, biostatistics, and real-world evidence offerings.
- Premier Research: Mid-size CRO with similar service portfolio spanning clinical development, RWE, and medical device evidence; competes for the same mid-market European pharma and biotech sponsors.
- Clinipace Worldwide: Mid-size CRO providing clinical research, regulatory affairs, and biostatistics services to mid-market biotech and pharma; similar size bracket and therapeutic focus to Kappa.
- MMS Holdings: Data-focused CRO providing biostatistics, clinical data management, regulatory submissions, and medical writing — overlapping tightly with Kappa's clinical development sub-services.
- APICES CRO: Parent organization and now the operating entity for Kappa Santé; APICES provides the same European clinical development, RWE, and medical device CRO services across Spain and France.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Kappa Sante social profiles
Digital presenceKappa Sante financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kappa Sante leadership team
Management profileNumber of profiles
Profiles2 records
Kappa Sante funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kappa Sante M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kappa Sante
What does Kappa Sante do?
Kappa Santé is a European contract research organization delivering clinical development, real-world evidence (RWE), health economics and outcomes research (HEOR), and clinical evidence services for medical devices. Offerings are organized around four core solutions — Early Clinical Development, Late Clinical Development, RWE & HEOR, and Medical Devices — delivered through sub-services spanning clinical strategy, study design, country and site feasibility, regulatory and ethics submissions, project management, clinical monitoring, data management and biostatistics, medical writing, and clinical safety. The portfolio supports sponsors from first European execution through late-phase delivery and post-marketing evidence generation.
Is Kappa Sante a public or private company?
Kappa Sante is a private company. It is classified as corporate owned and is currently acquired.
When was Kappa Sante founded?
Kappa Sante was founded in 2003. It employs 11 to 50 people.
Where is Kappa Sante based?
Kappa Sante is headquartered in Paris, France, in the Europe region.
How does Kappa Sante make money?
One revenue line is on record: CRO Professional Services.
Who are Kappa Sante's main competitors?
Broad incumbents on record are Medpace, Eurofins Scientific and ICON plc. Direct peers are NAMSA, Worldwide Clinical Trials, Cytel, Premier Research, Clinipace Worldwide, MMS Holdings and APICES CRO.
Does Kappa Sante have an API?
No public API is recorded for Kappa Sante.
What industry is Kappa Sante in?
Kappa Sante's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAEAL, Data Management, Reporting & Regulatory Submissions for Central Labs, with a secondary code of HLAJADAF, Clinical Trials Authorization & Oversight (GCP). Its NAICS code is 5417 and its SIC code is 8731.